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Aggregation of misfolded proteins is a characteristic of
several neurodegenerative diseases. The huntingtin
amino-terminal fragment with extended polyglutamine
repeat forms aggregates closely associated with chaper-
ones both in the cytoplasm and the nucleus. As each cel-
lular compartment contains distinct chaperones and
because the molecular mechanisms controlling poly-
glutamine aggregation are largely unknown, we decided
to investigate the influence of different cellular environ-
ments on the aggregation of this pathological protein. We
found that aggregation of a protein containing a poly-
glutamine stretch of pathological length is abolished
when its expression is targeted to the endoplasmic reticu-
lum. Once retrogradely transported outside of the endo-
plasmic reticulum, the aggregation-prone polyglutamine
containing protein recovers its ability to aggregate. When
expressed in the mitochondria, a protein containing 73
glutamines is entirely soluble while the nucleo-cytosolic
equivalent has an extremely high tendency to aggregate.
Our data imply that polyglutamine aggregation is a prop-
erty restricted to the nucleo-cytosolic compartment and
suggest the existence of compartment-specific co-factors
promoting or preventing aggregation of pathological pro-
teins. Implications for recombinant proteins production
will be discussed.
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